Christopher Toomey
Ophthalmology · San Diego, CANPI 1578922092
Payments from drug & device makers
What this record shows
This record is dominated by grants: $75,000 of the $77,508 with a category attached, or 96.8%. Alcon Research LLC accounts for 96.8% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $75,128 and has fallen 97.1% since, to $2,210 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 18 payments — averaging $4305.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$75K
- Alnylam Pharmaceuticals Inc.$2K
- Alcon$145
- AbbVie$125
- Apellis Pharmaceuticals, Inc.$29
- Oyster Point Pharma, Inc.$25
- plus $44 from 2 others
What the payments were for
- Consulting fees$2,1403%
- Grants$75,00097%
- Food & beverage$3680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 1 | $75,000 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,140 |
| Alcon | 6 | $145 |
| AbbVie | 6 | $125 |
| Apellis Pharmaceuticals, Inc. | 1 | $29 |
| Oyster Point Pharma, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Amgen | 1 | $21 |
How this compares
$77,508 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 11 | $526 |
| Prednisolone Acetate | 11 | $370 |
| Latanoprost | 18 | $232 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in San Diego
- Robert WeinrebSan Diego$520K
- Eric NudlemanSan Diego$343K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.